Supporting Information

A Double-Leg Donor-Acceptor Molecular Elevator: New Insight into Controlling the Distance of Two Platforms

Zhi-Jun Zhang, a Min Han, a,b Heng-Yi Zhang, and Yu Liu *,a

yuliu@nankai.edu.cn

Table of Contents

1. Synthesis and characterization of compounds	S2-S6
2. ESI-MS spectrum of [1·2-2H]·2PF ₆	S7-S7
3. ¹ H- ¹ H COSY and NOESY spectra of 3 -2H·2PF ₆ and 4 -2H·4PF ₆	S7-S9
4. ¹ H NMR investigation of 1:1 complex	S9-S10
5. Emission spectra of compounds	S10-S10
6. ¹ H NMR investigation of 4 -2H·4PF ₆	S11-S11
7. Energy-minimized structure of 4 -2H·4PF ₆	S12-S12
8. Acid/base controlled process investigated by UV/vis and fluorescent	nce S13-S15

^a Department of Chemistry, State Key Laboratory of Elemento-Organic Chemistry, Nankai University, Tianjin 300071, P. R. China

^b Traditional Chinese Medicine Research & Development Institute of Tasly Academy, Tianjin Tasly Group Co. Ltd., Tianjin 300410, P. R. China

General methods and materials: All chemicals were commercially available unless noted otherwise. All chemicals were commercially available unless noted otherwise. 1¹, 2-2H·2PF₆², 5-2H·2PF₆², 6-2H·4PF₆², and 3,5-di(*tert*-butyl)benzyl azide³ were prepared according to the literature procedure. NMR data were recorded on Bruker AV400 spectrometer, and chemical shifts were recorded in parts per million (ppm). Mass spectra were recorded using Agilent 6520 Q-TOF LC/MS (ESI). Absorption spectra were recorded on Shimadzu UV/Vis spectrometer UV-2401PC. Fluorescence spectra were measured with an Edinburgh Analytical Instruments FLS920 spectrometer (Edinburgh Instruments, Edinburgh, U.K.) employing the time correlated single photon counting technique.

Preparation of 3-2H·2PF₆:

2-2H·2PF₆ (81 mg, 0.08 mmol), **1** (100 mg, 0.10 mmol), 3,5-di(*tert*-butyl)benzyl azide (60 mg, 0.24 mmol), Cu(MeCN)₄PF₆ (112 mg, 0.30 mmol) and 2,6-lutidine (3.2 mg, 0.03 mmol) were mixed in 3 mL CH₃CN and 1 mL CH₂Cl₂, then stirred at room temperature for 24 h. After the solvent was reduced under vacuum, the residue was purified by column chromatography over silica gel (eluent: CH₂Cl₂/MeOH = 100:1) to afford the **3**-2H·2PF₆ as a dark green solid (104 mg, 53%). ¹H NMR (400 MHz, CD₃CN) δ 8.40 (s, 4H), 8.03 (s, 2H), 7.45 (m, 6H), 7.35 (s, 4H), 7.23 (d, J = 1.4 Hz, 4H), 7.02–6.87 (m, 16H), 5.56 (s, 4H), 5.12 (s, 4H), 4.82–4.68 (m, 4H), 4.62–4.47 (m, 4H), 4.30 (m, 4H), 4.16 (m, 4H), 4.1–3.86 (m, 28H), 3.80 (m, 4H), 3.71–3.59 (m, 8H), 3.55 (m, 4H), 2.85–2.75 (m, 4H), 2.17–2.13(m, 4H), 1.49–1.41 (m, 4H), 1.30 (s, 36H), 1.05 (t, J = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CD₃CN) δ 162.4, 158.8, 151.6, 147.4, 146.9, 143.5, 135.0, 130.5, 129.7, 128.7, 125.7, 125.3, 124.4, 123.9, 122.5, 121.5, 115.1, 112.9, 103.3, 70.6, 70.1, 68.4, 68.1, 67.8, 61.4, 54.1, 50.2, 45.7, 38.4, 34.5, 30.5, 24.5, 23.1, 22.2, 13.9. HRMS (ESI): m/z: [M–2PF₆]²⁺ calcd for C₁₂₆H₁₅₈N₁₀O₂₂²⁺ 1082.0787; found: 1082.0785.




Figure S1. ¹H NMR spectrum of **3**-2H·2PF₆ (CD₃CN, 400 MHz, 298 K).




Figure S2. ¹³C NMR spectrum of **3-**2H·2PF₆ (CD₃CN, 100 MHz, 298 K).

Preparation of 4-2H·4PF₆:

To a solution of 3-2H·2PF₆ (40 mg, 0.016 mmol) in 5 ml CH₃CN was added 5 ml CH₃I. The mixture was heated at 40 °C for 4 days. Then the solvent was removed under reduced pressure. When the crude product was suspended in acetone (40 ml), a saturated aqueous solution of NH₄PF₆ was added and the mixture stirred until the suspension became clear. The solvent was removed, and water (100 ml) was added to the residue. The resulting mixture was then filtered, washed with water, and dried to afford 4-2H·4PF₆ as a pale green solid (32 mg, 72%). ¹H NMR (400 MHz, CD₃CN) δ 8.46 (s, 2H), 8.44 (s, 4H), 7.58 (s, 2H), 7.50 (d, J = 8.7 Hz, 4H), 7.41 (br, 4H), 7.38 (d, J = 1.4 Hz, 4H), 6.98 (s, 4H), 6.94 (m, 12H), 5.73 (s, 4H), 5.21 (s, 4H), 4.82 (m, 4H), 4.57-4.51 (m, 4H), 4.32 (m, 4H), 4.28 (m, 6H), 4.17-4.08 (m, 12H), 4.02 (m, 8H), 3.96–3.90 (m, 12H), 3.87–3.82 (m, 4H), 3.73–3.66 (m, 8H), 3.56 (m, 4H), 2.83 (m, 4H), 2.22 (m, 4H), 1.46 (m, 4H), 1.34 (s, 36H), 1.06 (t, J = 7.3 Hz, 6H). ¹³C NMR (100 MHz, CD₃CN) δ 163.1, 158.2, 152.8, 148.0, 147.5, 140.4, 131.8, 131.3, 130.3, 129.8, 129.3, 127.4, 126.4, 126.0, 125.0, 124.5, 124.2, 122.1, 115.6, 113.5, 103.9, 71.3, 70.7, 68.7, 68.3, 58.7, 58.4, 50.5, 46.3, 39.2, 39.0, 35.3, 31.1, 25.0, 23.7, 14.5. HRMS (ESI): m/z: $[M-4PF_6]^{4+}$ calcd for $C_{128}H_{164}N_{10}O_{22}^{4+}$ 548.5508; found: 548.5515.




Figure S3. ¹H NMR spectrum of **4-**2H·4PF₆ (CD₃CN, 400 MHz, 298 K).





Figure S4. ¹³C NMR spectrum of **4**-2H·4PF₆ (CD₃CN, 100 MHz, 298 K).






Figure S5. The HRMS spectrum of **4-**2H·4PF₆ (Top:experiment;bottom:calculation)




Figure S6. ESI-MS (low resolution) spectrum of the equimolar mixture of **1** and **2-**2H·2PF₆ in CHCl₃/CH₃CN (1:1). The major peak at m/z 837 is assigned to the dication $[\mathbf{1}\cdot\mathbf{2}\text{-}2H]^{2+}$, the peak at m/z 1026 is assigned to $[\mathbf{1}+Na]^{+}$




Figure S7. The ¹H-¹H COSY spectrum (400 MHz, 298 K, CD₃CN) of 3-2H·2PF₆.




Figure S8. The $^{1}\text{H-}^{1}\text{H}$ COSY spectrum (400 MHz, 298 K, CD₃CN) of 4-2H·4PF₆.




Figure S9. The NOESY spectrum (400 MHz, 298 K, CD₃CN) of $4\text{-}2\text{H}\cdot4\text{PF}_6$.




Figure S10. The ${}^{1}\text{H}$ - ${}^{1}\text{H}$ COSY spectrum (400 MHz, 298 K, CD₃CN) of **4**-2H·4PF₆ after addition of 3.0 equivalents P_{1} -tBu.




Figure S11. Partial ¹H NMR spectra (400 MHz, CDCl₃/CD₃CN = 1:1, 5 mM, 298 K) of (a) **2-**2H·2PF₆, (b) 1:1 adduct [**1·2-**2H]·2PF₆, and (c) host **1**. * = peaks of solvents and H₂O.




Figure S12. Partial ¹H NMR spectra (400 MHz, CDCl₃/CD₃CN = 1:1, 5 mM, 298 K) of 1:1 adduct $[1\cdot2-2H]\cdot2PF_6$

The association constant of [1·2-2H]·2PF₆ was calculated by single-point method. From the integral ratio of complexed and uncomplexed H_j of 2-2H·2PF₆, $K_a = [(15.96/16.96) \times 5.0 \times 10^{-3}] / [(1.0/16.96) \times 5.0 \times 10^{-3}]^2 \text{ M}^{-1} = 5.4 \times 10^4 \text{ M}^{-1}$.




Figure S13. Emission spectra of a) **1**, b) **2-**2H·2PF₆, c) [**1·2-**2H]·2PF₆, and d) **4-**2H·4PF₆. (CHCl₃/CH₃CN = 1:1, 0.01 mM, excited at λ = 375 nm)




Figure S14. Partial ¹H NMR spectra (400 MHz, CD₃CN, 5 mM, 298 K) of (a) the uncomplexed host **1**, (b) **4**-2H·4PF₆, and (c) the uncomplexed dumbbell-shaped thread **6**-2H·4PF₆. * = peaks of solvent and H₂O.





Figure S15. Molecular energy minimization of **4**-2H·4PF₆ with the platform situated on the upper level (top) and the lower level (bottom). The geometries were optimized by the molecular mechanics method with dreiding forcefield.






Figure S16. (Top) UV/vis spectra of a) **4**-2H·4PF₆, b) after the addition of 4.0 equiv of P_1 –tBu to **4**-2H·4PF₆ and c) after the addition of 4.0 equiv of TFA to **4**-2H·4PF₆ treated by base. (CH₃CN, 0.01 mM)

(Bottom) Plot of absorption at 377 nm on successive addition of 4.0 equiv of P_1 –tBu (B, D, F, H) and TFA (C, E, G, I).

In the dilute solution (0.01 mM), the spectral change can be only found below 450 nm, which should be attributed to the distance change of anthracene and NDI. After addition of base, the increase of absorption was consistent with the previous result on the divalent pseudorotaxane which also exhibits the similar change after addition of base Bu_3N .¹




Figure S17. UV/vis spectra of a) **4**-2H·4PF₆, b) after the addition of 3.0 equiv of P₁-tBu to **4**-2H·4PF₆ and c) after the addition of 3.0 equiv of TFA to **4**-2H·4PF₆ treated by base. (CH₃CN, 1.5 mM)




Figure S18. UV/vis spectra of a) **6**-2H·4PF₆, and b) after the addition of 3.0 equiv of P_1 –tBu to **6**-2H·4PF₆. (CH₃CN, 1.5 mM).

After the addition of excessive base to the uncomplexed axle molecule **6**-2H·4PF₆, a strong CT absorption can be observed. It is noteworthy that a peak at 610 nm can be found which should be attributed to the anion radical state of NDI unit.⁴ And this peak can be also found in the absorption spectrum of **4**-2H·4PF₆ after the addition of base (Figure S17b), which suggests that the phosphazene base not only moves the

elevator but also forms complex with the NDI unit as an electron donor. Moreover, through comparing the spectral change of 4-2H·4PF $_6$ and 6-2H·4PF $_6$ after addition of base, it can be suggested that after subtracting the CT interaction between P_1 -tBu and NDI, the CT interaction between anthracene and NDI should be weakened.




Figure S19. Emission spectra of a) **4**-2H·4PF₆, b) after the addition of 3.0 equiv of P₁–tBu to **4**-2H·4PF₆ and c) after the addition of 3.0 equiv of TFA to **4**-2H·4PF₆ treated by base. (CH₃CN, 0.01 mM, excited at $\lambda = 375$ nm)

References:

[1] Jiang, W.; Han, M.; Zhang, H. Y.; Zhang, Z. J.; Liu, Y. Chem.-Eur. J. 2009, 15, 9938-9945.

[4] Guha, S.; Saha, S. J. Am. Chem. Soc. 2010, 132, 17674–17677.

^[2] Jiang, Q.; Zhang, H. Y.; Han, M.; Ding, Z. J.; Liu, Y. Org. Lett. 2010, 12, 1728–1731.

^[3] Gassensmith, J. J.; Barr, L.; Baumes, J. M.; Paek, A.; Nguyen, A.; Smith, B. D. *Org. Lett.* **2008**, *10*, 3343–3346.